Navigation Links
Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Date:7/22/2014

MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their US prescription cough cold collaboration. Under this collaboration, POC requires the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. As a result of achieving POC, Vernalis will make a milestone payment to Tris.

Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+™ based extended release liquid equivalents to existing immediate release prescription cough/cold treatments. The financial terms of this licensing deal are not disclosed.

Ian Garland, CEO of Vernalis commented "Three of our five cough cold programmes in our collaboration with Tris have now achieved proof-of-concept and for the most advanced of those programmes (Tuzistra™ XR) an NDA has already been submitted to the FDA. We are delighted with the momentum building in our Tris collaboration and are looking forward to continuing success over the remainder of the year".

Ketan Mehta, CEO of Tris commented "This is an exciting time for both our companies with the continuing progress of the prescription cough cold portfolio and we look forward to the further success of our partnership with Vernalis."

Notes to Editors

About Vernalis  
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com.

About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A.

For more information, please visit www.trispharma.com

Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.


'/>"/>
SOURCE Tris Pharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. ISSI Announces Fiscal 2014 Third Quarter Conference Call
2. Sono-Tek Announces Third Quarter Results
3. Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
4. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
5. The Epilepsy Market Will Grow 2 Percent Annually Through 2022 with Expanding Uptake of Third-Generation Brands
6. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
7. China Nepstar Chain Drugstore Reports Third Quarter 2013 Financial Results
8. Veracyte, Inc. Announces Third Quarter 2013 Financial Results
9. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
10. Bayers Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community
11. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):